Dr. Gerngross is the co-founder and CEO of Adimab and a venture partner at SV Life Sciences. He is also the co-founder of Kreogene, an oncology drug development company. Previously, he was a co-founder of GlycoFi, Inc. (SVLSF III) and served as the company's Chief Scientific Officer until its acquisition by Merck and Co in June of 2006. In addition, Dr. Gerngross holds faculty positions at the Engineering School at Dartmouth College, as well as the Departments of Biology and Chemistry. Dr. Gerngross has a M.S. degree in Chemical Engineering and a Ph.D. in Molecular Biology from the Technical University of Vienna. From 1989-93 he was a visiting scientist and later Postdoctoral Fellow at MIT.
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverXSponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health SciencesSponsored · Whitepaper
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting© 2007-2022, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.